RA Capital Exits 5% Stake, Dumping 4.18M LENZ Shares in Three Days
LENZ is trading near its 52-week low of $2.8 (11% above the low) on elevated volume (2.6× avg).
Summary
RA Capital sold about 4.18 million LENZ shares over three sessions at weighted averages of $3.36 down to $2.98, cutting its stake to 0.2% and falling below the 5% threshold on October 29. The exit lands one day after a Q3 report that beat on VIZZ sales but missed on losses.
Key Events · Ownership and Investor Activity · LENZ
-
RA Capital Liquidates Common Position
Sold 2,718,684 shares on 10/29, 665,226 on 10/30 and 794,913 on 11/02/2026 — 4,178,823 shares total — leaving 70,533 shares, all warrant-derived, or 0.2% of the class.
-
Selling Prices Fell Each Session
Weighted average price declined from $3.36 (range $3.16-$3.58) to $3.27 ($3.05-$3.38) to $2.98 ($2.90-$3.18), indicating the block was absorbed at progressively lower levels.
-
Five Percent Threshold Crossed
The Reporting Persons ceased to be beneficial owners of more than five percent of common stock on October 29, 2026, ending 13D reporting obligations.
-
Follows Weak Q3 Print
The exit came one day after the October 28 Q3 report showing VIZZ sales of $2.6 million, up about 50% sequentially, alongside an adjusted loss of 99 cents a share versus 91-cent consensus.
Analysis · LENZ · Life Sciences
RA Capital, one of LENZ's anchor healthcare investors, sold roughly 4.18 million shares across October 29, October 30 and November 2, dropping its stake to 0.2% of the class and below the 5% reporting threshold. The selling was not orderly: the weighted average price fell from $3.36 to $3.27 to $2.98 over the three sessions, meaning the block was being pushed into a weakening market. What remains is 70,533 shares, and those are only obtainable by exercising warrants — so the fund's common stock position is effectively gone. This matters because it removes a large, sophisticated holder from the register right after a Q3 print (October 28) that showed VIZZ sales of $2.6 million but a wider-than-expected adjusted loss of 99 cents a share. A specialist biotech investor choosing to liquidate entirely rather than hold through the launch ramp is a meaningful vote of no confidence in the near-term setup.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LENZ was trading at $3.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $95.8M. The 52-week trading range was $2.80 to $32.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.